Recent studies show α-eleostearic acid and its methyl ester induce ferroptosis in senescent cells, reducing inflammation and improving muscle function in aged mice without toxicity, with clinical tri...
Senolytic and senomorphic therapies, including Rubedo’s RLS-1496 in Phase 1 trials, target senescent cells to treat aging diseases, boosted by AI-driven discovery and rising investment. New seno...
Senolytic and senomorphic therapies are advancing with compounds like RLS-1496 and α-ESA-me targeting senescent cells. Experts highlight challenges in biomarkers and safety, pushing for personalized ...
Recent breakthroughs in senolytic and senomorphic therapies, including polyunsaturated lipids inducing ferroptosis, are advancing clinical trials for age-related diseases, with a focus on safety and b...
Exploring recent advances in senolytic and senomorphic therapies, including dasatinib-quercetin and immune-based approaches, to combat age-related diseases like Alzheimer’s and sarcopenia. New t...
Recent studies reveal that supplementing Roseburia inulinivorans enhances muscle strength by up to 30% in mice, with human trials showing promise for probiotic therapies against sarcopenia. New resear...
Emerging research shows that enhancing mRNA surveillance mechanisms like nonsense-mediated decay can reduce neurodegeneration, with innovative therapies targeting tau aggregation offering new hope. Re...
Recent studies uncover autophagy’s dual role in aging, suggesting early enhancement through lifestyle may delay decline, while late-stage inhibition in senescent cells could reduce inflammation,...
Recent studies on hydra’s negligible senescence overturn traditional aging models, suggesting aging is adaptable and offering clues for anti-aging biotech interventions. New research reveals hyd...
Recent studies highlight autophagy’s conflicting roles in aging: protective early on but sustaining harmful senescent cells under stress, with the threshold model guiding new clinical approaches...
